Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 153 Jul 18 – Oct 15, 2026
- Disclosed funding
- $5.2B 123 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| M MironidCompany profile Mironid develops small-molecule medicines for inherited kidney disease, with a lead programme targeting autosomal dominant polycystic kidney disease. Mironid develops small-molecule medicines for inherited kidney disease, with a lead programme targeting autosomal dominant polycystic kidney disease. | $46M | Series B | Biotech | United Kingdom | Investors | |
| LT LifeMine TherapeuticsCompany profile Develops fungal genome-derived therapeutics for organ transplant rejection Develops fungal genome-derived therapeutics for organ transplant rejection | $263M | Series D+Series EUndisclosed | Biotech | United States | Investors | |
| VB Vedanta BiosciencesCompany profile Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection | $60M | Growth | Biotech | United States | Investors | |
| Q QuantHealthCompany profile AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment | $45M | Series B | Biotech | Israel | Investors | |
| CL CND Life SciencesCompany profile Develops biomarker-based diagnostic tests for neurodegenerative diseases Develops biomarker-based diagnostic tests for neurodegenerative diseases | Undisclosed | Growth | Biotech | United States | Investors | |
| C Uses genomic surveillance to identify hospital infection outbreaks and sources | $3.5M | Pre-SeedPre-seed | Biotech | United States | Investors | |
| I Whole-genome sequencing and bioinformatics platform for precision oncology | $31M | Series B | Biotech | United States | Investors | |
| DB Dash BioCompany profile Dash Bio provides automated bioanalysis for preclinical and clinical drug testing. Dash Bio provides automated bioanalysis for preclinical and clinical drug testing. | $30M | Series A | Biotech | United States | Investors | |
| RT Developing best-in-class radiopharmaceuticals for cancer treatment | $70M | Series CSeries C+ | Biotech | United States | Investors | |
| AT Adjuvia TherapeuticsCompany profile Adjuvia develops oral nanoparticle therapies intended to address mitochondrial dysfunction, starting with its ATI-105 program for rare diseases. Adjuvia develops oral nanoparticle therapies intended to address mitochondrial dysfunction, starting with its ATI-105 program for rare diseases. | $8M | Seed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 18, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Circle Pharma, Inc., Solstice Oncology, Superluminal Medicines
8rounds2led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Oxford Science Enterprises
OMass Therapeutics, ReEmerge, Inc., Vivid Dx
5rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.